The agreement with GSK is more to support their research focus and not a specific drug pipeline, said Jonathan Hunt, CEO, Syngene International
Throwing more light on the partnership Jonathan Hunt, CEO, Syngene International said it is a multi-year agreement. It is a discovery research partnership where scientist of both the companies will work together to help GSK accelerate their research projects and bring in new medicine for patients.
“It is under the discovery space, where scientist will look for new breakthroughs in innovative medicines, so that they can go into the next phase of clinical testing,” said Hunt.
It is in areas of chemical synthesis, medicinal chemistry, computational chemistry, said Hunt.
He also clarified that it is more supporting GSK in their research focus and not a specific drug pipeline.
Hunt said the company as of now was happy with all the strategic partnerships/collaborations they have had with BMS, Amgen, Baxter etc and are always on lookout for more.
Currently, he said the company is working with 16 of the 20 top Biotech Pharma companies in the world with around 300 active clients.Making good progress in broadening the reach Syngene has, he added.